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Abstract Lysophosphatidic acid (LPA) and sphingosine 1-phos-
phate (Sph-1-P) are known as structurally related bio-active
lipids activating platelets through their respective receptors.
Although the receptors for LPA and Sph-1-P have been recently
identified in various cells, the identification and characterization
of ones in platelets have been reported only preliminarily. In this
report, we first investigated the distinct modes of LPA and Sph-
1-P actions in platelet activation and found that LPA functioned
as a much stronger agonist than Sph-1-P, and high concentra-
tions of Sph-1-P specifically desensitized LPA-induced intracel-
lular Ca2+ mobilization. In order to identify the responsible
receptors underlying these observations, we analyzed the LPA
and Sph-1-P receptors which might be expressed in human
platelets, by RT-PCR. We found for the first time that Edg2, 4,
6 and 7 mRNA are expressed in human platelets.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Sphingosine 1-phosphate (Sph-1-P), one of the sphingolipid
metabolites, has been demonstrated to function as a lipid
mediator which is involved in cell motility [1,2], mitogenesis
[3,4] and cell shape changes including neurite retraction [5]
and regulation of angiogenesis [6]. Recent studies have sug-
gested that Sph-1-P acts both intracellularly and extracellu-
larly to cause various biological responses [7^9].
In platelets, Sph-1-P is abundantly stored intracellularly
[10], and released upon stimulation with thrombin or 12-O-
tetradecanoylphorbol 13-acetate (TPA) [10,11]. Sph-1-P func-
tions as an extracellular mediator for aggregation and intra-
cellular Ca2 mobilization in platelets, although weakly
[10,11]. In these studies, however, the characterization of re-
ceptor molecule(s) for this lipid has not been challenged [10].
Very recently, receptors for lysophosphatidic acid (LPA) and
Sph-1-P have been identi¢ed in various cells [12^18]; the Edg
family, which are the class of seven transmembrane G protein-
coupled receptors for lysophospholipids, comprises at least
seven members, Edg1^Edg7 [17^19]. Speci¢c receptors for
Sph-1-P are Edg1, 3, 5 [20^25] and those for LPA are Edg2,
4, 7 [13,15,18,26]. Although Edg1 is a high a⁄nity receptor
for Sph-1-P, it has been demonstrated that LPA also acts on
Edg1 with a low a⁄nity [27]. In contrast, the LPA receptor
Edg2 has been suggested to function as a possible low a⁄nity
receptor for Sph-1-P in human osteosarcoma MG63 cells [28].
Although a ligand for Edg6 has not been clearly identi¢ed yet,
it is postulated to be a Sph-1-P receptor from the structural
resemblance with the Sph-1-P receptors so far identi¢ed [17].
In addition, the presence of another class of G protein-
coupled receptor for LPA, named PSP24, was discovered
[29,30].
In this work, we investigated the distinction and relation of
modes of action of LPA and Sph-1-P in human platelet acti-
vation and examined the expression of the corresponding re-
ceptors in human platelets.
2. Materials and methods
2.1. Materials
The following materials were obtained from the indicated suppliers:
Sph-1-P (Biomol, Plymouth Meeting, PA, USA); LPA (Sigma, St.
Louis, MO, USA); thrombin (Mochida Pharmaceutical Co., Tokyo,
Japan); ionomycin (Calbiochem, San Diego, CA, USA); fura2-AM
(Dojindo Laboratories, Kumamoto, Japan).
2.2. Platelet preparation
Washed human platelets for intracellular Ca2 mobilization and
platelet aggregation were prepared as described previously [31] and
¢nally suspended in a bu¡er containing 138 mM NaCl, 3.3 mM
NaH2PO4, 2.9 mM KCl, 1.0 mM MgCl2, 1 mg/ml glucose, and
20 mM HEPES (pH 7.4), at a cell density of 3U108/ml. When platelet
aggregation was measured, the suspensions were supplemented with
1 mM CaCl2 and 500 Wg/ml of ¢brinogen. When platelet intracellular
Ca2 concentration ([Ca2]i) measurement was performed, the suspen-
sions were supplemented with 1 mM CaCl2 or EGTA, as indicated.
All experiments using intact platelet suspensions were performed at
37‡C.
Human platelets for mRNA isolation were prepared as follows.
200 ml of blood containing 15% of acid citrate dextrose solution
(0.8% citric acid, 2.2% trisodium citrate, 2.45% glucose) was collected
from healthy adult volunteers. The blood samples were centrifuged at
1000 rpm for 20 min at room temperature. Platelet-rich plasma, ob-
tained from the upper one-third of the blood sample, was transferred
to a new tube for another centrifugation (900 rpm for 2 min) to avoid
contamination with leukocytes. The platelet-rich plasma was then
transferred to another tube and mixed with an equal volume of phos-
phate bu¡ered saline (PBS) containing 15% acid citrate dextrose so-
lution, followed by 1 WM prostaglandin E1 addition. The sample was
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passed through Sepacell PLX-5A-ILS (Asahi Medical Co., Ltd.); the
column was used for exclusion of leukocytes, and the £ow-through
sample was centrifuged (3000 rpm for 10 min at room temperature),
and the resultant plasma supernatant was carefully removed from the
platelet pellet. The pellet was washed with PBS containing 15% acid
citrate dextrose solution and 1 WM prostaglandin E1. For successful
analysis in applying RT-PCR, it was crucial to con¢rm that platelet
preparations contained no contaminating cells. To estimate contami-
nation in the suspension, a hemocytometer was used for cell counting.
We con¢rmed that platelets were more than 99.99% pure, by estimat-
ing the ratio of white blood cells, if any, to platelets.
2.3. Preparation of polymorphonuclear leukocytes
For preparation of polymorphonuclear (PMN) leukocytes, 50 ml of
blood treated with heparin (as an anticoagulant) was collected from
healthy adult volunteers. The sample was carefully layered over an
equal volume of Polymorphprep1 (Nycomed Pharma AS, Oslo, Nor-
way), and centrifuged at 500Ug for 30 min at 20‡C. The lower band,
formed after centrifugation, consisted of PMN leukocytes. The cells
were diluted by addition of 0.45% NaCl and centrifuged.
2.4. Cell culture
Jurkat is a human T-lymphocyte cell line from an acute T-cell
leukemic patient. Jurkat cells were obtained from the American
Type Culture Collection and were cultured in RPMI 1640 containing
10% fetal bovine serum, 100 U/ml penicillin and 100 Wg/ml strepto-
mycin.
2.5. Platelet aggregation
This process was determined in a Platelet Ionized Calcium Aggre-
gometer (Chrono-Log, Havertown, PA, USA) under continuous stir-
ring at 1000 rpm. The instrument was calibrated with a platelet sus-
pension for zero light transmission and the bu¡er for 100%
transmission. The increase in light transmission caused by platelet
aggregation was continuously recorded. For quantitative evaluation
of platelet aggregation, results were expressed as the maximum change
of light transmission within 5 min after stimulation.
2.6. [Ca2+]i measurement
[Ca2]i measurement was performed with the use of the Ca2-sen-
sitive £uorophore fura2 as described previously [32] except that the
£uorescence measurements were made using a FS100 (Kowa, Tokyo,
Japan). The [Ca2]i values were determined from the ratio of fura2
£uorescence intensity at 340 and 380 nm excitation.
2.7. Isolation and RT-PCR of mRNAs from platelets, PMN leukocytes
and Jurkat cells
The mRNAs of platelets, PMN leukocytes and Jurkat cells, pre-
pared as described above, were isolated by QuickPrep Micro mRNA
Puri¢cation Kit (Pharmacia). Aliquots of mRNA preparation were
frozen at 380‡C until use. Based upon the nucleotide sequences of
the human Edg family (Edg1^7), PSP24 and platelet factor 4 (PF4) in
the database, oligonucleotide primers were prepared (Table 1). RT-
PCR was carried out in a Thermal Cycler (GeneAmp PCR system
9700, PE Applied Biosystems) using the SuperScript1 One-Step1
RT-PCR System (Life Technologies) with the template mRNA (50
ng) under the following conditions: (1) 50‡C for 30 min; (2) 94‡C
for 2 min; (3) 94‡C for 15 s; (4) 55‡C for 30 s; (5) 72‡C 30 s; (6)
repeat of steps 3^5 for 40 cycles; and (7) 72‡C for 1 min. When EDG6
primers were used for RT-PCR, the annealing temperature was
changed from 55‡C to 58‡C at step 4. RT-PCR products were visu-
alized on 2% agarose gel electrophoresis, and their nucleotide sequen-
ces were con¢rmed with a £uorescent DNA sequencer (ABI-377, PE
Applied Biosystems).
3. Results
3.1. Distinct modes of platelet aggregation and intracellular
Ca2+ mobilization induced by Sph-1-P and LPA
LPA is a potent platelet agonist, while Sph-1-P is a weak
one. As shown in Fig. 1, 10 WM LPA induced a strong and
irreversible platelet aggregation; Sph-1-P, at a concentration
as high as 40 WM, induced only a weak and reversible aggre-
gation. When platelet intracellular Ca2 mobilization was
measured in the presence of extracellular Ca2, LPA induced
a marked increase in intracellular Ca2 concentrations in a
dose-dependent manner (Fig. 2). The response induced by
Sph-1-P was much weaker, as was the case with platelet ag-
gregation (Fig. 2). When platelets were suspended in Ca2-free
bu¡er, which was further supplemented with EGTA (¢nal 1
mM), similar results were obtained. However, maximum Ca2
mobilization was obtained with 10^20 WM for LPA; above
these concentrations, the LPA-induced response weakened for
unknown reason(s) (data not shown). Accordingly, LPA func-
tions as a strong platelet agonist, but Sph-1-P functions as a
weak one in terms of aggregation and intracellular Ca2 mo-
bilization.
3.2. Desensitization of LPA-induced platelet intracellular Ca2+
mobilization by Sph-1-P
It was shown that LPA and Sph-1-P function as an extra-
cellular mediator for platelet activation [11,33^35], Further-
more, it has been suggested that LPA and Sph-1-P may share
membrane surface receptor(s) because they have common
structural features [10,36]. We performed desensitization ex-
periments with these two lipids for the intracellular Ca2 mo-
bilization in platelets. LPA (5 WM) induced irreversible aggre-
gation and increase in intracellular Ca2 concentrations (Figs.
1B and 2). The pretreatment with Sph-1-P (40 WM) inhibited
the LPA (5 WM)-induced intracellular Ca2 mobilization in
platelets (Fig. 3). In contrast, Sph-1-P (40 WM) did not a¡ect
the response induced by ionomycin (50 nM) or thrombin (0.04
U/ml) (Fig. 3). The speci¢c desensitization of LPA-induced
Ca2 mobilization by Sph-1-P supported again the idea that
LPA and Sph-1-P may share cell surface receptor(s) in human
platelets.
3.3. Expression of lysophospholipid receptors for human
platelets
In order to search the expression of lysophospholipid re-
ceptors in human platelets, we investigated mRNA expression
Table 1
Primers of RT-PCR for Edg family and PSP24
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of Edg family and PSP24 receptors by RT-PCR, since North-
ern blot analysis seemed practically impossible for platelets,
which contain a very small amount of mRNA. The mRNAs
of Edg1-7 and PSP24 are all detected in Jurkat human T-
lymphocytes, which were hence used as positive controls to
con¢rm that the prepared primers worked properly (Table 1
and Fig. 4A, lanes 1^8). Furthermore, mRNA of platelet fac-
tor 4 (PF4), which is known to be speci¢cally expressed in
platelets, was ampli¢ed from human platelet mRNA prepara-
tion (Fig. 4B, lane 9), con¢rming that our preparation of
platelet mRNA was successful. When the platelet mRNA
preparation was used as a template for RT-PCR, the mRNAs
of Edg2, 4, 6 and 7 were clearly detected (Fig. 4B, lanes 2, 4, 6
and 7). When the PMN leukocyte mRNA preparation was
used, mRNAs of Edg1-6 and PSP24 were detected (Fig. 4C,
lanes 1^8). The absence of ampli¢cation of the Edg1, Edg3,
Edg5 and PSP24 mRNAs in platelets, which were clearly ex-
pressed in leukocytes, further excluded the possibility of leu-
kocyte mRNA contamination in the platelet mRNA prepara-
tion (Fig. 4B,C).
4. Discussion
LPA and Sph-1-P are a newly described family of lipid
mediators, inducing human platelet aggregation [11,34,36].
In our previous work, we observed that Sph-1-P desensitizes
LPA-induced platelet aggregation, and suggested that Sph-1-P
and LPA share a common receptor(s) in platelets [10]. Very
recently, Gueguen et al. con¢rmed this and further revealed a
precise distinction in platelet-activating activities among vari-
ous structurally related lysophospholipid molecules [36]. In
that work, they also searched expression of Edg family
mRNAs in human platelets by RT-PCR, but failed to detect
Fig. 1. A: Platelet aggregation induced by LPA or Sph-1-P. Human platelets were challenged with 10 WM LPA (b) or 40 WM Sph-1-P (a), as
indicated by arrows. B: Platelet aggregation induced by various concentrations of LPA (open circles) or Sph-1-P (closed circles) is shown. Re-
sults are expressed as means of two typical determinations.
Fig. 2. Platelet intracellular Ca2 mobilization induced by LPA or
Sph-1-P. Fura2-loaded platelets supplemented with 1 mM CaCl2
were challenged with various concentrations of LPA (open circles)
or Sph-1-P (closed circles). The results are the values of peak in-
creases after stimulation and are from a single experiment represen-
tative of three. In separate experiments, the basal [Ca2]i and the in-
crease in [Ca2]i induced by 40 WM Sph-1-P were found to be
88 þ 11 nM and 128 þ 12 nM (mean þ S.D., n = 4), respectively.
Fig. 3. Desensitization of LPA-induced platelet intracellular Ca2
mobilization by prior addition of Sph-1-P. Platelets supplemented
with 1 mM EGTA were preincubated with 40 WM Sph-1-P for
1 min. The cells were then stimulated with 50 nM ionomycin
(Iono), 0.04 U/ml of thrombin (Thr), or 5 WM LPA, and the in-
creases in [Ca2]i (the ratio of fura2 £uorescence) were measured.
The results are expressed as a percentage of control (without Sph-1-
P pretreatment). The ratio of fura2 £uorescence of control experi-
ments (100%) was 1.52 þ 0.10 (ionomycin), 1.47 þ 0.06 (thrombin),
and 1.47 þ 0.15 (LPA). Columns and error bars represent the
mean þ S.D. (n = 3).
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any (Edg1 to Edg4 were examined). Based upon these prelimi-
nary experiments, they suggested that lysophospholipid recep-
tors in human platelet might not be a member of the Edg
family, but rather an unknown, new type of receptor(s),
with a comment that they could not exclude a technical failure
in the RT-PCR method.
In this work, we ¢rst showed that LPA acts as a strong
agonist for platelet aggregation and intracellular Ca2 mobi-
lization, but Sph-1-P as a weak one. Secondly, we demon-
strated that Sph-1-P desensitized LPA-induced intracellular
Ca2 mobilization, which is consistent with results of desensi-
tization experiments on platelet aggregation [10,36]. These re-
sults further suggested that Sph-1-P and LPA may share cell
surface receptor(s). We claimed in the previous paper that
Sph-1-P itself is a platelet-activating agonist, but the desensi-
tization experiments in this study rather intimate an alterna-
tive concept that Sph-1-P released from activated platelets
may play a regulatory role toward LPA-induced platelet acti-
vation. Thirdly, and most importantly, the expressions of
Edg2, Edg4, Edg6 and Edg7 were revealed for the ¢rst time
in human platelets by RT-PCR with properly prepared
mRNA from highly puri¢ed platelet preparations. Although
at present we cannot completely exclude the possibility that
the new type of so far unidenti¢ed lysophospholipid recep-
tor(s) can bind both LPA and Sph-1-P, as Gueguen et al.
suggested [36], the most likely possibility deduced from our
results is that one (or more) of the LPA receptors among
Edg2, Edg4 and Edg7 expressed in human platelets may
bind Sph-1-P with a low a⁄nity and may function as a com-
mon lysophospholipid receptor. The idea is consistent with
the results of platelet aggregation and intracellular Ca2 mo-
bilization, in which LPA acts more strongly than Sph-1-P
(Figs. 1B and 2). The second possibility is that Edg6, the
ligand of which has not been identi¢ed yet, may function as
a Sph-1-P receptor in a functional collaboration with LPA in
human platelets.
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